Article
Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Clinical cancer research : an official journal of the American Association for Cancer Research - 2 Aug 2022
Xia Liang, Mei Jiandong, Kang Ran, Deng Senyi, Chen Yaohui, Yang Ying, Feng Gang, Deng Yulan, Gan Fanyi, Lin Yidan, Pu Qiang, Ma Lin, Lin Feng, Yuan Yong, Hu Yang, Guo Chenglin, Liao Hu, Liu Chengwu, Zhu Yunke, Wang Wenping, Liu Zheng, Xu Yuyang, Li Kaidi, Li Chuan, Li Qingyun, He Ji, Chen Weizhi, Zhang Xiaolong, Kou Yingli, Wang Yun, Wu Zhu, Che Guowei, Chen Longqi, Liu Lunxu
Abstract excerpt
PURPOSE: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a biomarker for early detection of molecular residual disease (MRD) and prediction of postoperative relapse in resected non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: Based on our prospective, multicenter cohort on dynamic monitoring of ctDNA in lung cancer surgery patients (LUNGCA), we enrolled 950 plasma samples obtained...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.